Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Biodesix outlined its Molecular Residual Disease strategy for the first time, spanning both tumor-informed and tumor-naive ctDNA monitoring approaches. The tumor-informed solution builds on a multi-year collaboration with Bio-Rad's Droplet Digital PCR, while the tumor-naive methylation-based assay runs on Thermo Fisher's Genexus platform; both will be validated with Memorial Sloan Kettering investigators. The company says the programs extend its focus beyond lung diagnostics into precision oncology, with data presentations planned at the AMP 2026 Annual Meeting in November and the San Antonio Breast Cancer Symposium in December.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.